GlassScriptPhysician profile
Monet W Bowling
NPI 1144424458
$2,401.71
in general payments reported to CMS, 2019-2025
34 companies · $1,116 in 2025
The $1,116 reported for 2025 was more than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33.94 · 2022: $48.88 · 2023: $617 · 2024: $586 · 2025: $1,116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,318.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $350.30 | 2022-2025 | Enhertu, Lynparza |
| Merck Sharp & Dohme LLC | $336.28 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $329.87 | 2023-2025 | Kisqali, Piqray |
| Janssen Biotech, INC. | $142.05 | 2023-2025 | Erleada, Talvey, Darzalex |
| Daiichi Sankyo INC. | $134.60 | 2023-2025 | Enhertu, Datroway |
| Coherus Oncology, INC. | $93.20 | 2023-2024 | |
| Eisai INC. | $87.82 | 2024-2025 | |
| Ethicon US, LLC | $80.27 | 2025 | Stratafix, Dermabond |
| Genentech USA, INC. | $68.60 | 2023-2024 | Tecentriq, Alecensa, Rozlytrek |
| Incyte Corporation | $66.44 | 2023-2025 | Jakafi, Zynyz, Niktimvo |
| Lilly USA, LLC | $46.94 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Sobi, INC | $45.73 | 2023-2025 | |
| Seagen INC. | $45.38 | 2023 | Tukysa, Adcetris |
| Takeda Pharmaceuticals U.S.A., INC. | $43.87 | 2024-2025 | Fruzaqla, Iclusig |
| Acrotech Biopharma INC. | $43.30 | 2025 | Beleodaq |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $42.14 | 2024-2025 | Libtayo |
| Emd Serono, INC. | $37.31 | 2023-2024 | Bavencio |
| Beone Medicines USA, INC. | $35.76 | 2025 | Brukinsa |
| Genmab U.S., INC. | $35.16 | 2023-2024 | Tivdak |
| Bayer Healthcare Pharmaceuticals INC. | $33.94 | 2019 | |
| Genzyme Corporation | $31.74 | 2023 | |
| Pfizer INC. | $27.15 | 2025 | |
| Azurity Pharmaceuticals, INC. | $25.53 | 2025 | Vivimusta |
| Abbvie INC. | $25.00 | 2025 | |
| Alexion Pharmaceuticals, INC. | $24.47 | 2025 | Ultomiris |
| Celltrion USA INC. | $23.84 | 2025 | Vegzelma |
| Davol INC. | $21.60 | 2022 | |
| Legend Biotech USA INC. | $21.45 | 2025 | Carvykti |
| E.R. Squibb & Sons, L.L.C. | $21.44 | 2024 | Opdivo |
| Elucent Medical | $18.09 | 2025 | |
| Cti Biopharma Corp. | $18.05 | 2023 | Vonjo |
| Accord Healthcare, INC. | $17.40 | 2025 | |
| Puma Biotechnology, INC. | $13.62 | 2023 | |
| Veracyte, INC. | $13.37 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monet Bowling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.